The effectiveness of aspirin for migraine prophylaxis
a systematic review
Keywords:
Migraine disorders, Headache, Aspirin, Platelet aggregation inhibitors, Therapeutics, Review [publication type]Abstract
CONTEXT AND OBJECTIVE: Many researchers have suggested that aspirin prevents migraines. However, the evidence is unclear. The aim of this study was to analyze the available evidence on the effect of aspirinas a migraine prophylactic. DESIGN AND SETTING: Systematic review, conducted at the Pontifícia Universidade Católica do Paraná, Brazil, and at the University of São Paulo, Brazil. METHODS: We performed electronic searches in the databases of MEDLINE/PubMed, Ebase, WEB OF SCIENCE, the World Health Organization, CENTRAL and OpenGrey, and we also searched manually for interventional studies published before April 2016 that compared the effects of aspirin with a control, in adults. Two authors independently extracted data on the publication, population recruited, intervention (aspirin dosage, follow-up and combined treatment) and main outcomes (frequency, severity and dura- tion of migraine). We evaluated the quality of the studies using the Cochrane risk-of-bias tool. RESULTS: Our search retrieved 1,098 references, of which 8 met the selection criteria for this systematic review. The total population was 28,326 participants (18-64 years old); most (96%) were men. The dosage varied from 50 to 650 mg/day across the studies. The risk of bias was generally low or unclear. The only outcome for which most of the studies included (6/8) reported a significant reduction was frequency of migraine, which was reduced at an aspirin dosage of at least 325 mg/day. CONCLUSION: Aspirin can reduce the frequency of migraines. However, the optimal dosage is unclear.
Downloads
References
Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743-800.
Diener HC, Solbach K, Holle D, Gaul C. Integrated care for chronic migraine patients: epidemiology, burden, diagnosis and treatment options. Clin Med (Lond). 2015;15(4):344-50.
Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. Headache. 2013;53(2):227-9.
Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-96.
Morillo LE, Alarcon F, Aranaga N, et al. Prevalence of migraine in Latin America. Headache. 2005;45(2):106-17.
Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52(10):1456-70.
Katsarava Z, Manack A, Yoon MS, et al. Chronic migraine: classification and comparisons. Cephalalgia. 2011;31(5):520-9.
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629-808.
Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012;52(6):930-45.
Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015;55 Suppl 2:103-22; quiz 123-6.
Members of the task force: Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur J Neurol. 2006;13(6):560-72.
Silberstein SD, Neto W, Schmitt J, Jacobs D; MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004;61(4):490-5.
Young WB, Siow HC, Silberstein SD. Anticonvulsants in migraine. Curr Pain Headache Rep. 2004;8(3):244-50.
Couch JR; Amitriptyline Versus Placebo Study Group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache. 2011;51(1):33-51.
Giacomozzi ARE, Vindas AP, Junior AAS, et al. Consenso latino-americano para as diretrizes de tratamento da migranea cronica [Latin American consensus on guidelines for chronic migraine treatment]. Arq Neuropsiquiatr. 2013;71(7):478-86.
Gales BJ, Bailey EK, Reed AN, Gales MA. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines. Ann Pharmacother. 2010;44(2):360-6.
Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988;296(6618):313-6.
Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821-47.
Benseñor IM, Cook NR, Lee IM, et al. Low-dose aspirin for migraine prophylaxis in women. Cephalalgia. 2001;21(3):175-83.
Diener HC. Low-dose aspirin for migraine prophylaxis in women. Cephalalgia. 2001;21(3):167-8.
Buring JE, Peto R, Hennekens CH. Low-dose aspirin for migraine prophylaxis. JAMA. 1990;264(13):1711-3.
Kurth T, Gaziano JM, Cook NR, et al. Migraine and risk of cardiovascular disease in women. JAMA. 2006;296(3):283-91.
Diener HC. Low-dose aspirin for migraine prophylaxis in women. Cephalalgia. 2001;21(3):167-8.
Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
Bousser MG, Chick J, Fuseau E, Soisson T, Thevenet R. Combined low-dose acetylsalicylic acid and dihydroergotamine in migraine prophylaxis. A double-blind, placebo-controlled crossover study. Cephalalgia. 1988;8(3):187-92.
Baldrati A, Cortelli P, Procaccianti G, et al. Propranolol and acetylsalicylic acid in migraine prophylaxis. Double-blind crossover study. Acta Neurol Scand. 1983;67(3):181-6.
Hosman-Benjaminse SL, Bolhuis PA. Migraine and platelet aggregation in patients treated with low dose acetylsalicylic acid. Headache. 1986;26(6):282-4.
Classification of headache: The ad hoc committee on classification of headache. Arch Neurol. 1962;6(3):173-6. Available from: http://jamanetwork.com/journals/jamaneurology/article-abstract/563669 Accessed in 2016 (Nov 16).
Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia. 1988;8 Suppl 7:1-96.
Masel BE, Chesson AL, Peters BH, Levin HS, Alperin JB. Platelet antagonists in migraine prophylaxis. A clinical trial using aspirin and dipyridamole. Headache. 1980;20(1):13-18.
O'Neill BP, Mann JD. Aspirin prophylaxis in migraine. Lancet. 1978;2(8101):1179-81.
Schramm SH, Moebus S, Özyurt Kugumcu M, et al. Use of aspirin combinations with caffeine and increasing headache frequency: a prospective population-based study. Pain. 2015;156(9):1747-54.
